Waters Corporation - Asset Resilience Ratio
Waters Corporation (WAT) has an Asset Resilience Ratio of 11.56% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read WAT total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Waters Corporation's Asset Resilience Ratio has changed over time. See Waters Corporation shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Waters Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see WAT market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $587.83 Million | 11.56% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $587.83 Million | 11.56% |
Asset Resilience Insights
- Moderate Liquidity: Waters Corporation has 11.56% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Waters Corporation Industry Peers by Asset Resilience Ratio
Compare Waters Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB |
Diagnostics & Research | 43.99% |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193 |
Diagnostics & Research | 55.11% |
|
Diagnos Laboratorium Utama PT Tbk
JK:DGNS |
Diagnostics & Research | 0.32% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Waters Corporation (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Waters Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.56% | $587.83 Million | $5.08 Billion | +4.42pp |
| 2024-12-31 | 7.14% | $325.36 Million | $4.55 Billion | -1.41pp |
| 2023-12-31 | 8.56% | $395.97 Million | $4.63 Billion | -6.14pp |
| 2022-12-31 | 14.70% | $482.25 Million | $3.28 Billion | -3.57pp |
| 2021-12-31 | 18.26% | $565.27 Million | $3.09 Billion | +2.89pp |
| 2020-12-31 | 15.38% | $436.69 Million | $2.84 Billion | +2.20pp |
| 2019-12-31 | 13.18% | $336.93 Million | $2.56 Billion | -28.16pp |
| 2018-12-31 | 41.34% | $1.54 Billion | $3.73 Billion | -18.58pp |
| 2017-12-31 | 59.92% | $3.20 Billion | $5.34 Billion | -0.42pp |
| 2016-12-31 | 60.34% | $2.81 Billion | $4.66 Billion | +15.48pp |
| 2015-12-31 | 44.86% | $1.91 Billion | $4.26 Billion | +2.75pp |
| 2014-12-31 | 42.11% | $1.63 Billion | $3.88 Billion | +3.99pp |
| 2013-12-31 | 38.12% | $1.36 Billion | $3.58 Billion | +4.73pp |
| 2012-12-31 | 33.39% | $1.06 Billion | $3.17 Billion | +0.44pp |
| 2011-12-31 | 32.95% | $897.36 Million | $2.72 Billion | +5.55pp |
| 2010-12-31 | 27.41% | $637.92 Million | $2.33 Billion | +12.25pp |
| 2009-12-31 | 15.15% | $289.15 Million | $1.91 Billion | +10.07pp |
| 2007-12-31 | 5.09% | $95.68 Million | $1.88 Billion | +0.15pp |
| 2002-12-31 | 4.94% | $49.94 Million | $1.01 Billion | -- |
About Waters Corporation
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, and other consumable products. It designs, manufactures, sells, and se… Read more